Back to results
US 11,891,426 B2Granted
CD19 variants
AssigneesAleta Biotherapeutics Inc., Regents of the University of Minnesota
InventorsRoy Lobb, Paul Rennert, Benjamin Hackel, Justin Klesmith
Life of this patent
Estimating the term…
Abstract
CD19 variants, methods of identifying CD19 variants, and methods of using such CD19 variants, e.g., for treating cancer, are described.
Claims10
A CD19 variant having at least 99% sequence identity to SEQ ID NO:2 wherein,
- the CD19 variant comprises amino acid substitutions at positions 62/64/66 of the amino acid sequence of SEQ ID NO:
- 2 selected from the following:
- S/V/S;
- G/V/R;
- S/R/R;
- T/V/P;
- S/R/S;
- E/R/P;
- E/W/R;
- E/V/V;
- D/L/P;
- A/R/L;
- W/S/S;
- T/R/Q;
- R/V/R;
- E/E/V;
- Y/S/R;
- D/V/M;
- W/V/A;
- TN/F;
- R/A/F;
- E/C/S;
- E/R/R;
- D/V/R;
- S/V/A;
- T/A/S;
- H/F/R;
- T/V/R;
- T/M/S;
- S/V/R;
- H/V/S;
- S/F/N;
- N/L/P;
- D/V/S;
- W/T/A;
- D/A/S;
- G/V/K wherein the CD19 variant has improved binding to an anti-CD19 antibody relative to a polypeptide comprising the amino acid sequence of SEQ ID NO:2;
- or
- the CD19 variant comprises amino acid substitutions at positions 62/64/66 of the amino acid sequence of SEQ ID NO:
- 2 selected from the following:
- Y/S/T;
- V/G/D;
- A/Q/T;
- V/E/E;
- wherein the CD19 variant is more resistant to protease cleavage relative to a polypeptide comprising the amino acid sequence of SEQ ID NO:2.
42 more elements
Dependencies are inferred from the claim text.